Recursion Pharmaceuticals, Inc. (RXRX)

8,60 -0,04 (-0,46%) Börsenschluss: 04:00PM EDT

Recursion Pharmaceuticals, Inc.

41 South Rio Grande Street
Salt Lake City, UT 84101
United States
385 269 0203
https://www.recursion.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 500

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Christopher C. Gibson Ph.D.	Co-Founder, CEO & Director	806,72k	2,18M	1983
Ms. Tina Marriott Larson	COO & President	702,24k	397,61k	1975
Dr. Blake C. Borgeson Ph.D.	Co-Founder & Director	40k	N/A	1982
Dr. Michael Secora Ph.D.	Chief Financial Officer	629,78k	3,62M	1983
Dr. David J. Mauro M.D., Ph.D.	Chief Medical Officer	674,74k	N/A	1965
Kevin Leggat	Vice President of Finance & Accounting	N/A	N/A	N/A
Mr. Benjamin Mabey M.S.	Chief Technology Officer	N/A	N/A	1983
Mr. Jared Allenbach	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Nathan Hatfield	Chief Legal Officer & General Counsel	N/A	N/A	N/A
Mr. Ryan Kelly	Chief Communications Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Recursion Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 1, Vorstand: 6, Shareholderrechte: 10, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.